# US 2024/0252491 A1 · Novel methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252491 A1
- Document ID: US20240252491A1
- Status: Published application
- Kind: A1
- Application number: 18/621,067
- Filed: 2024-03-28
- Published: 2024-08-01
- Earliest claimed: 2018-03-16
- Assignees: Intra-Cellular Therapies, Inc.
- Applicants: Intra-Cellular Therapies, Inc.
- Inventors: Gretchen SNYDER; Robert DAVIS; Lawrence P. WENNOGLE
- Web page: https://patentgrep.com/patent/US20240252491A1

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/38: having sulfur as a ring hetero atom
- A61K 31/381: having five-membered rings
- A61K 31/42: Oxazoles
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61K 38/07: Tetrapeptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/24: Antidepressants
- C07D 471/16: Peri-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of treating acute depression, comprising administering to a patient in need thereof, a therapeutically effective amount of a Compound of Formula I:
wherein the Compound of Formula I is in the form of the tosylate salt,
wherein the method comprises once daily administration of a unit dosage for oral administration in the form of a tablet or capsule comprising the compound of Formula I in tosylate salt form in an amount equivalent to 1 to 60 mg of free base, and a pharmaceutically acceptable diluent or carrier; and
wherein the acute depression is bipolar depression, or depressive episodes associated with bipolar disorder.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 2)

The method according to claim 2, wherein the the depressive episodes are selected from acute major depressive episode, acute short-duration depressive episode, and acute recurrent brief depressive episode).

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 2)

The method according to claim 2, wherein the method further comprises the concurrent administration of an NMDA receptor antagonist.

### Claim 18 (depends on 2)

The method according to claim 2, wherein the method further comprises the concurrent administration of a NMDA receptor allosteric modulator.

### Claim 19 (depends on 2)

The method according to claim 2, wherein the method provides the patient with an acute response to treatment with the Compound of Formula.

### Claim 20 (depends on 2)

The method according to claim 2, wherein the patient has not responded to, or has not responded adequately to, or who suffers undesirable side effects from, treatment with another antidepressant agent.

### Claim 21 (depends on 2)

The method according to claim 2, wherein the Compound of Formula I is administered as monotherapy.

### Claim 22 (depends on 2)

The method according to claim 2, wherein the method does not put the patient at risk for sedation, dissociation, abuse, misuse, or suicidal ideation, or does not result in hypertension within four hours after administration of a dose of the compound of Formula I.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 2)

The method according to claim 2, wherein the acute depression is bipolar depression.

### Claim 26 (depends on 2)

The method according to claim 2, wherein the acute depression is depressive episodes associated with bipolar disorder.

### Claim 27 (depends on 26)

The method according to claim 26, wherein the depressive episode is an acute major depressive episode.

### Claim 28 (depends on 2)

The method according to claim 2, wherein the depression is alleviated within one week of treatment.

### Claim 29 (depends on 2)

The method according to claim 2, wherein the patient shows an acute response to treatment within less than 2 weeks of treatment.
